News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

OncLive Peer Exchange: Diagnosis of Myelodysplastic Syndrome

Original Publication Date
Article Source
External Web Content
The panel provides perspective on the diagnosis of MDS, or Myelodysplastic Syndromes. They discuss recent innovation, including next-gen testing to enhance the efficacy of treatments. Watch these experts here!

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Original Publication Date
Article Source
External Web Content
Abstract BACKGROUND Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth…

AML Research Efforts in Full Swing After Decades of Stagnation

Original Publication Date
Article Source
External Web Content
After decades of few advances and stagnant treatment approaches, which mainly comprised 7+3 chemotherapy, the acute myeloid leukemia (AML) paradigm now has several agents approved, and plenty of ongoing trials are exploring other novel therapies alone and in combination…

The Falling, Wandering and Crashing Business of Cancer Treatment Side Effects

Original Publication Date
Article Source
External Web Content
With neuropathy as a result of treatment comes a whole host of issues. The first one I can think of? Oops, there goes the wine! In more ways than one, actually, as wine is probably one of the last things you can enjoy while undergoing chemo. And not only can you not enjoy it, but…

Woyach Highlights Progress and Next Steps in CLL Paradigm

Original Publication Date
Article Source
External Web Content
With therapeutic additions to the treatment paradigm of chronic lymphocytic leukemia (CLL), it is now a question of which regimen to give patients in the frontline setting, explained Jennifer A. Woyach, MD. “In the frontline setting, our new options for targeted therapy include…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families